Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, March 13, 2014 12:17:53 PM
I can't seem to copy links well anymore, the one paper title is:
Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure - Oct 3, 2013, which states:
When these in vitro (on cells) and in vivo (on mice) results were compared comprehensively, we found that the toxicity in vivo was not as significant as that in vitro. There are several possible reasons: (1) The micelles in vivo exist mainly in the blood system, which is a dynamic environment, whereas the in vitro studies are performed in a relatively static environment,
I think there are some humna phase testing beginning for delivering cancer fighting compounds, but I am unclear on that or status of.
Again, I must caution, I am pushing the limits of my contemporary knowledge to allow me to keep it all in proper context. Addtionally, other activities are preventing me from delving extremely deep into the various on-going research efforts being made by many investigators.
My biggest concern is not the toxicity, but that other investigators and groups are exploring this area for anti-virals, and while Diwan and others have patents, I know form experienc ein other areas that if someone with deep pockets wants to do something, patents dont always prevent it. First successful human trials is most important! Thus my previous statements about taking too much time.
Good luck to all.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM